XML 64 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Identifiable Intangible Assets and Goodwill (Tables)
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
 As of December 31, 2021As of December 31, 2020
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization		Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization
Finite-lived intangible assets
Developed technology rights(a)
$73,346 $(53,732)$19,614 $73,040 $(50,532)$22,508 
Brands922 (807)115 922 (774)148 
Licensing agreements and other2,284 (1,299)985 2,292 (1,187)1,106 
76,552 (55,838)20,714 76,255 (52,493)23,762 
Indefinite-lived intangible assets
Brands827 827 827 827 
IPR&D3,092 3,092 3,175 3,175 
Licensing agreements and other513 513 573 573 
4,432 4,432 4,575 4,575 
Identifiable intangible assets(b)
$80,984 $(55,838)$25,146 $80,830 $(52,493)$28,337 
(a)The increase in the gross carrying amount primarily reflects $500 million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.
(b)The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.
Schedule of Indefinite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
 As of December 31, 2021As of December 31, 2020
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization		Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization
Finite-lived intangible assets
Developed technology rights(a)
$73,346 $(53,732)$19,614 $73,040 $(50,532)$22,508 
Brands922 (807)115 922 (774)148 
Licensing agreements and other2,284 (1,299)985 2,292 (1,187)1,106 
76,552 (55,838)20,714 76,255 (52,493)23,762 
Indefinite-lived intangible assets
Brands827 827 827 827 
IPR&D3,092 3,092 3,175 3,175 
Licensing agreements and other513 513 573 573 
4,432 4,432 4,575 4,575 
Identifiable intangible assets(b)
$80,984 $(55,838)$25,146 $80,830 $(52,493)$28,337 
(a)The increase in the gross carrying amount primarily reflects $500 million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.
(b)The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.
Schedule of Expected Amortization Expense
The following provides the expected annual amortization expense:
(MILLIONS)20222023202420252026
Amortization expense$3,279 $2,936 $2,686 $2,500 $2,449 
Schedule of Goodwill
The following summarizes the components and changes in the carrying amount of Goodwill:
(MILLIONS)
Total(a)
Balance, January 1, 2020
$48,181 
Additions(b)
727 
Other(c)
648 
Balance, December 31, 2020
49,556 
Additions— 
Other(c)
(348)
Balance, December 31, 2021
$49,208 
(a)As a result of the reorganization of our commercial operations during the fourth quarter of 2021 (see Note 17), we were required to estimate the relative fair values of our PC1 and Hospital organizations to determine any reallocation of goodwill. We completed this analysis and determined that no goodwill was required to be reallocated. As a result, our entire goodwill balance continues to be assigned within the Biopharma reportable segment.
(b)Additions primarily represent the impact of measurement period adjustments related to our Array acquisition (see Note 2A).
(c)Other represents the impact of foreign exchange.